Mark J. Fitzgerald

2.9k total citations · 1 hit paper
35 papers, 2.4k citations indexed

About

Mark J. Fitzgerald is a scholar working on Immunology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark J. Fitzgerald has authored 35 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark J. Fitzgerald's work include NF-κB Signaling Pathways (6 papers), Liver physiology and pathology (5 papers) and Asthma and respiratory diseases (5 papers). Mark J. Fitzgerald is often cited by papers focused on NF-κB Signaling Pathways (6 papers), Liver physiology and pathology (5 papers) and Asthma and respiratory diseases (5 papers). Mark J. Fitzgerald collaborates with scholars based in Canada, United States and Australia. Mark J. Fitzgerald's co-authors include N Fausto, Robert E. Bellas, Marcello Arsura, Min Wu, Stephanie L. Schauer, Gail E. Sonenshein, David H. Sherr, Eric M. Webber, G E Sonenshein and Douglas I. Katz and has published in prestigious journals such as Science, The EMBO Journal and Nature Biotechnology.

In The Last Decade

Mark J. Fitzgerald

35 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells.

1996 546 citations Min Wu, Robert E. Bellas et al. profile →

Peers

Countries citing papers authored by Mark J. Fitzgerald

Since Specialization

Citations

This map shows the geographic impact of Mark J. Fitzgerald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Fitzgerald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Fitzgerald more than expected).

Fields of papers citing papers by Mark J. Fitzgerald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Fitzgerald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Fitzgerald. The network helps show where Mark J. Fitzgerald may publish in the future.

Co-authorship network of co-authors of Mark J. Fitzgerald

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Fitzgerald. A scholar is included among the top collaborators of Mark J. Fitzgerald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Fitzgerald. Mark J. Fitzgerald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·Ian Pavord, Thomas B. Casale, Jonathan Corren, Mark J. Fitzgerald, Yamo Deniz, Arman Altincatal, (unknown), (unknown), Amr Radwan, Juby A. Jacob‐Nara, Paul J. Rowe, William W. Busse	10
2	A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases 2023 ·BMC Medical Informatics and Decision Making ·Abdollah Safari, John Petkau, Mark J. Fitzgerald, Mohsen Sadatsafavi	1
3	Microbiome therapeutics and patent protection 2020 ·Nature Biotechnology ·Mark J. Fitzgerald, (unknown)	11
4	Health literacy and chronic disease management: drawing from expert knowledge to set an agenda 2016 ·Health Promotion International ·Iraj Poureslami, Laura Nimmon, Irving Rootman, Mark J. Fitzgerald	122
5	A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy 2009 ·Journal of Clinical Epidemiology ·Mohsen Sadatsafavi, Neal Shahidi, Fawziah Marra, Mark J. Fitzgerald, Kevin Elwood, Na Guo, Carlo A. Marra	27
6	Marijuana and chronic obstructive lung disease: a population-based study 2009 ·Canadian Medical Association Journal ·Wan C. Tan, Christine Lo, Audrey De Jong, Xing Li, Mark J. Fitzgerald, W M Vollmer, Sonia Buist, Don D. Sin	142
7	Survival benefit of coronary-artery bypass grafting accounted for deaths in those who remained untreated 2008 ·Journal of Cardiothoracic Surgery ·Boris Sobolev, Guy Fradet, Robert Hayden, Lisa Kuramoto, Adrian R. Levy, Mark J. Fitzgerald	1
8	Delay in admission for elective coronary-artery bypass grafting is associated with increased in-hospital mortality 2008 ·BMC Health Services Research ·Boris Sobolev, Guy Fradet, Robert Hayden, Lisa Kuramoto, Adrian R. Levy, Mark J. Fitzgerald	17
9	Fluoroquinolones for the Treatment of Pulmonary Tuberculosis 2007 ·Drugs ·Susanne Moadebi, (unknown), Mark J. Fitzgerald, Kevin Elwood, Fawziah Marra	85
10	Evaluating Health-Related Quality-of-Life Studies in Paediatric Populations 2005 ·PharmacoEconomics ·Mirella De Civita, Dean A. Regier, (unknown), Aslam H. Anis, Mark J. Fitzgerald, Carlo A. Marra	215
11	Randomized trial of problem-based versus didactic seminars for disseminating evidence-based guidelines on asthma management to primary care physicians 2004 ·Journal of Continuing Education in the Health Professions ·Marc White, Gaëtane Michaud, George Pachev, David S. Lirenman, (unknown), Mark J. Fitzgerald	44
12	Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc 1999 ·Oncogene ·Mark J. Fitzgerald, Marcello Arsura, Robert E. Bellas, William Yang, Min Wu, (unknown), Koren K. Mann, Ronald A. DePinho, Gail E. Sonenshein	14
13	c-Myc Promotes Survival of WEHI 231 B Lymphoma Cells from Apoptosis 1997 ·Current topics in microbiology and immunology ·Min Wu, William Yang, Robert E. Bellas, Stephanie L. Schauer, Mark J. Fitzgerald, (unknown), G E Sonenshein	21
14	Cryptogenic Organizing Pneumonia A Report of 25 Cases and a Review of the Literature 1995 ·Medicine ·Kadria Alasaly, Néstor L. Müller, David N. Ostrow, P Champion, Mark J. Fitzgerald	98
15	Rapid DNA binding by nuclear factor kappa B in hepatocytes at the start of liver regeneration. 1995 ·PubMed ·Mark J. Fitzgerald, Eric M. Webber, Jesse Donovan, N Fausto	184
16	Transforming growth factor-α expression during liver regeneration after partial hepatectomy and toxic injury, and potential interactions between transforming growth factor-α and hepatocyte growth factor 1993 ·Hepatology ·Eric M. Webber, Mark J. Fitzgerald, Pamela I. Brown, (unknown), Nelson Fausto	120
17	The effect of increasing doses of β-agonists on airflow in patients with chronic airflow limitation 1993 ·Respiratory Medicine ·Roman Jaeschke, Gordon Guyatt, (unknown), Joanne Morris, Andrew R. Willan, William E. McIlroy, (unknown), (unknown), (unknown), Mark J. Fitzgerald, Michael T. Newhouse	17
18	Extensive Volcanism Associated with the Separation of Australia and Antarctica 1984 ·Science ·J. B. Jones, Mark J. Fitzgerald	15
19	The Nilpena ureilite, an unusual polymict breccia: implications for origin 1982 ·Geochimica et Cosmochimica Acta ·A. L. Jaques, Mark J. Fitzgerald	46
20	ADELAIDE AND BENCH CRATER — MEMBERS OF A NEW SUBGROUP OF THE CARBONACEOUS CHONDRITES 1977 ·Meteoritics ·Mark J. Fitzgerald, J. B. Jones	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact